Clene Inc. 8-K

What Happened

• Clene Inc. filed a Form 8-K on May 5, 2026 announcing an underwriting agreement with Canaccord Genuity LLC to sell 1,000,000 shares of common stock at $7.00 per share. The offering is expected to close on May 6, 2026, subject to customary closing conditions.
• The company estimates gross proceeds of $7.0 million and net proceeds of approximately $6.4 million after underwriting discounts, commissions and estimated offering expenses. Maxim Group LLC and D. Boral Capital LLC are acting as financial advisors.

Key Details

• Shares offered: 1,000,000 common shares at $7.00 per share (gross proceeds $7.0M; est. net ~$6.4M).
• Underwriting fees: 6.5% of gross proceeds; approximately 85% of that goes to the underwriter and about 15% is split (~7.5% each) to the two financial advisors.
• Estimated other offering expenses: ~$140,000.
• Lock-up: Company, certain officers, directors and affiliated entities agreed to a 60‑day lock-up restricting sales of common stock subject to customary exceptions.
• Use of proceeds: general corporate purposes and to fund preparation/filing of the CNM‑Au8 new drug application, continued access to CNM‑Au8 in expanded access protocols, a future confirmatory Phase 3 trial, manufacturing expansion, potential commercialization, and early‑stage R&D.

Why It Matters

• This financing will raise modest capital (net ≈ $6.4M) and dilute existing shareholders by 1,000,000 new shares; the lock-up limits insider selling for 60 days.
• Proceeds are earmarked primarily to advance Clene’s lead program, CNM‑Au8, including NDA preparation and Phase 3 activities, which are material near‑term development and potential commercialization steps for the company.
• Investors should note underwriting costs reduce net proceeds and that the offering was made under the company’s effective Form S‑3 registration statement.